1 / 9

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2

Phase 2. Treatment Experienced. Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2. Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4 . Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3 LONESTAR-2 Trial: Features.

boaz
Download Presentation

Sofosbuvir + Peginterferon + Ribavirin in Genotype 2 or 3 LONESTAR-2

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Phase 2 TreatmentExperienced Sofosbuvir + Peginterferon + Ribavirin in Genotype 2or 3 LONESTAR-2 LawitzE, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  2. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Features Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  3. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Patient Demographics Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  4. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Design 0 12 24 Week SVR12 Drug DosingSofosbuvir: 400 mg once dailyPeginterferon alfa-2a: 180 µg once weeklyRibavirin (weight-based and in 2 divided doses): 1000 mg/day if < 75 kg or 1200 mg/day if ≥ 75 kg Sofosbuvir + Peginterferon + Ribavirin N =47 Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  5. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Results LONESTAR-2 Trial: SVR12 by HCV Genotype 42/47 22/23 20/24 Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  6. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Results LONESTAR-2 Trial: SVR 12 by HCV Genotype Five Treatment Failures- 1 patient with GT2 lost to follow-up- 2 patients with GT3 with virologic relapse- 2 patients with GT3 lost to follow-up 42/47 22/23 20/24 Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  7. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Results LONESTAR-2 Trial: SVR12 by Cirrhosis Status 9/9 13/14 10/12 10/12 Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  8. Sofosbuvir + PEG + RBV in Treatment-Experienced HCV GT 2 or 3LONESTAR-2 Trial: Adverse Events Source: Lawitz E, et al. 64th AASLD; Washington, DC. 2013. Abstract LB-4.

  9. This slide deck is from the University of Washington’s Hepatitis C Online and Hepatitis Web Study projects. Hepatitis C Onlinewww.hepatitisc.uw.edu Hepatitis Web Studyhttp://depts.washington.edu/hepstudy/ Funded by a grant from the Centers for Disease Control and Prevention.

More Related